JAK inhibitors for the treatment of vitiligo
Vitiligo is an autoimmune disease involving melanocyte-targeting T cells initiated by environmental and genetic factors. Steroids and tacrolimus have been used as topical treatments. Recently, novel topical agents targeting Janus kinase (JAK), a family of tyrosine kinases that regulates cytokine signaling, have emerged. Ruxolitinib is the first approved in vitiligo therapy. Furthermore, ritlecitinib is currently under clinical trials for oral treatment of active vitiligo. In this review, we discuss the possibility of topical JAK inhibitors as promising options for the treatment of vitiligo with regard to their mechanism of action, efficacy and safety.
Source: Journal of Dermatological Science - Category: Dermatology Authors: Shintaro Inoue, Tamio Suzuki, Shigetoshi Sano, Ichiro Katayama Source Type: research
More News: Autoimmune Disease | Clinical Trials | Dermatology | Environmental Health | Genetics | Prograf | Science | Skin | Tacrolimus | Vitiligo